List of Biologics Companies in Belgium - 38

Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance, AbolerIS Pharma is developing novel and unique therapeutic approaches to finely regulate the immune system by inducing immune tolerance and preserving useful immune responses in inflammatory, autoimmune, and degenerative diseases.

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating rare and severe peripheral protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by systemic amyloidosis. Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.

Animab is a new venture designed to address the changing needs of animal production. Using proprietary research discoveries, Animab targets the emerging science and new possibilities in the gut. The interdisciplinary team integrates cutting-edge research, animal science, and biotechnology for product breakthroughs in animal health, cost-efficiencies and sustainability. Led by an experienced group of experts with expertise in a range of relevant domains from vaccines, biotechnology, business management and international marketing, Animab is dedicated to offering a safe and sustainable way to ensure animal performance. More information: www.animab.com.

We are Antleron, a nimble team that will revolutionise medicine by leading the development of next generation advanced therapies and medical devices. By merging the potential of cells, biomaterials, biologics, 3D printing and bioreactors we will accelerate the engineering of medicinal products, devices and processes that will change health care and result in a better life for all. The Antleron business philosophy is to create sustainable ventures through risk & reward sharing partnerships based on the adoption of our game changing team know-how and technology platforms.

AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first in class Plug & Play vaccine platform with a patented DNA based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.

ATB Therapeutics is a pioneering biopharmaceutical company building a new line of attack against cancer. atbtherapeutics has developed the atbody; a game-changer biologic format designed to broaden the therapeutic window of antibody-based therapies. Only our proprietary and versatile plant-based atbiofarm technology enables single-step manufacturing of our novel class of therapeutic atbodies. The resulting therapeutics offer a novel mechanism of action, avoiding major cancer cell resistance, and provide a promising, life-changing therapy for hard-to-treat and refractory cancer.

BioSenic is an innovative company with the objective of addressing important unmet medical needs in the areas of immunity, auto-immune diseases and organ repair.

Bioxodes is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of therapeutics for patients with thrombo-inflammatory diseases. We leverage our deep understanding of the thrombotic and inflammatory processes to design novel product candidates with an aim to address unmet medical needs.

Cell Signaling Technology for Organ Repair and Regeneration We care for liver Our advanced therapy aims to restore liver function thanks to immunomodulatory and regenerative properties of Hepastem

Cell Matters is a company operating in the cell therapy industry that enhances cell therapy productivity through cryopreservation services and GMP compliance.

A biotech company dedicated to the discovery and development of protein therapeutics using its proprietary alphabody™ technology. Alphabodies are robust and versatile protein scaffolds, unrelated to immunoglobulins, and inspired by naturally occurring motives. Complix’s proprietary Cell Penetrating Alphabody (CPAB) technology allows it to access a broad range of intracellular disease related targets that are considered “intractable” by currently available drug formats, such as antibodies and small molecules.

Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets. This technology platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments. Confo Therapeutics was spun out of Vrije Universiteit Brussel (VUB) and VIB in 2015. Supported by international life-science focused investors and led by an experienced team of entrepreneurial professionals and scientists from successful biopharmaceutical companies, Confo Therapeutics benefits from the rich scientific and innovative ecosystem in Belgium.

CuraVac is a clinical-stage biotech developing a new class of targeted therapeutic vaccines / immunotherapies for autoimmune diseases. Our first therapeutic vaccine is for myasthenia gravis (MG). Preclinical work is ongoing for other autoimmune diseases including MS and GBS. Future studies will focus on Graves' diease, Hashimoto's disease, Type 1 Diabetes, ...

Immunotherapy is a Bio-pharmaceutical company that develops a safe and highly effective approach for cancer treatment, focusing on Glioblastoma multiforme using its patented Gliovac/ERC1671.

Driving discovery and solving challenges for partners across LNP formulation and RNA chemistry | www.etherna.be | www.ethernamanufacturing.com We are an RNA technology company, with over 30 years’ experience, offering professional partnership to pharma and biotech with an emerging or established interest in RNA therapeutics. Our expert team supports start-up, early stage and late stage projects by using our proprietary platforms across RNA chemistry, LNP formulation and Process Technology, to drive new pipeline development or resolve manufacturing challenges for our partners.

Eurogentec, part of Kaneka Corporation, is an international biotechnology supplier, based in Belgium, who specializes in genomics and proteomics. The company is fully ISO 9001, ISO 13485 certified, cGMP accredited by the Belgian Ministry of Health and approved by the US FDA for the commercial manufacturing of a biologic for the US market. Eurogentec was founded in 1985. Through its three inter-related business units (BU), the company provides high quality products to scientists involved in the life science, biotechnology, diagnostic and pharmaceutical markets. The life science BU specializes in Genomics (e.g. Lab scale to Large scale Oligonucleotides, PCR/qPCR Kits & Reagents and Assay Dispensing Service) and Proteomics (e.g. catalog and custom peptides & antibodies including a 28-Day Speedy protocol, assay kits and Proprietary Dyes & Quenchers). The In Vitro Diagnostics BU provides technical and project support for contract manufacturing of GMP oligonucleotides and Taq DNA polymerases for use in Molecular Diagnostic applications. The Biomanufacturing BU is a GMP Biomanufacturer specialized in the technology transfer, process development, scale-up and manufacturing of proteins, plasmids and vaccines for pre-clinical, clinical and commercial uses, all according to FDA and EMA requirements.

ExeVir Bio, a spin out of VIB, is harnessing its Llama-derived antibody (VHH) technology platform to generate robust antiviral therapies providing broad protection against coronaviruses. ExeVir Bio is using a highly innovative and clinically validated VHH technology to develop treatments for viral infections that may pose a significant global threat. Our lead compound, an enhanced variant of VHH72-Fc binds to a unique epitope that is conserved in SARS-CoV-1 and SARS-CoV-2 viruses and this binding prevents these viruses from entering the cell. The importance of this approach is that it could be used both as a therapeutic and prophylactic. Therapeutic use could help slow viral replication in the lungs, reduce inflammation, and give patients valuable time to raise their own productive immune response. Prophylactic use could support the ringfencing of an outbreak, protect healthcare workers, caregivers and support those at increased risk of severe illness from Covid-19.

Exothera is a contract research, development, and manufacturing organization (CDMO) dedicated to viral vector and nucleic acids production. As a technology-driven company, Exothera provides best-in-class bioprocessing expertise that capitalizes on the best and most innovative manufacturing technologies developed within the Univercells group. The company delivers accelerated discovery services as well as process development/optimization to rapidly reach GMP clinical and commercial production of viral vectors and nucleic acids. At Exothera and Univercells, Our mission is to make life-changing therapies available to all. As a Univercells company, Exothera capitalizes on novel manufacturing technologies and best-in-class bioprocessing expertise to provide custom-made process optimization and GMP clinical and commercial production of viral vectors. Based on its extensive technology expertise, Exothera selects technologies to optimally answer customer needs for cost-effective and agile viral vector manufacturing. Company number: 0744643660 VAT: BE0744643660

Flamingo is pioneering RNA-targeted therapies for oncology with state-of-the art chemistries and a clinical-stage pipeline targeting undruggable transcription factors and splice variants. Flamingo Therapeutics has a Phase II trial (PEMDA-HN) evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC). Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Andera Partners, Bpifrance Large Venture, Bpifrance through its FABS and Fonds Biothérapies Innovantes et Maladies Rares funds, Eurazeo - Kurma Partners, Perceptive Advisors, PMV, Pontifax, Sphera, funds managed by Tekla Capital Management LLC and VIB.

Fujirebio is a global leader in the field of high-quality in vitro diagnostics (IVD). We are an R&D-driven company constantly developing new technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care. Our global teams located in Japan, Asia, Europe and the US focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and critical materials in order to supply, develop or manufacture diagnostic solutions on a wide variety of platforms. Through this business model, we ensure that the potentially life-changing diagnostic markers meet the largest global need in the shortest possible time. Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions. Founded in 1950 in Tokyo, Japan, Fujirebio has over the years concluded a number of successful acquisitions of best-in-class IVD companies. Examples include Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Today, Fujirebio’s global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network. Fujirebio is today a consolidated subsidiary of H.U. Group Holdings, Inc. (listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1,200 people in Asia, Europe and America.

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjogren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.a r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

Huvepharma is a fast growing global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products. The company also manufactures and markets enzymes for food, feed and industrial applications. Huvepharma is a privately owned company headquartered in Sofia, Bulgaria.

Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases. The company’s unique technology platform can address a wide range of autoimmune and immunologic diseases. Imotopes™ are modified synthetic peptides, which specifically block improper immune activity. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no effective therapeutic alternative and has the potential to cure patients without impairing their immune defenses. Our vision is to become a leader in the field of active specific immunotherapy and to prevent, stop and potentially cure autoimmune diseases. Headquartered in Liège, Belgium, Imcyse was founded as a spin-off of the Catholic University of Leuven (KULeuven). Imcyse’s Imotope™ technology platform is protected by a robust, international intellectual property portfolio. Our lead Imotope™, IMCY-0098, is in phase 2 clinical testing for early onset type 1 diabetes.

MRM Health NV is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome.The company is based in a Center of Expertise for microbiome research and development in the biotech cluster in Ghent, Belgium, and has a strategic partnership with the VIB, with top research groups in both microbiome analysis and ecology and in host biology and disease research. The Company is strategically supported by strong local and international investors, including Ackermans & van Haaren, DuPont, MRM Technologies, Qbic II and VIB and has a corporate collaboration with DuPont Nutrition Biosciences in the development of microbiome-based therapeutics for metabolic diseases. MRM Health's proprietary technology platform brings live microbial therapeutics development to the next level by combining rationally selected strains into synergistic consortia through a proprietary optimization process.

myNEO Therapeutics is a distinguished biopharmaceutical powerhouse, dedicated to pioneer breakthrough immunotherapies to fight cancer. myNEO Therapeutics is leveraging its ImmunoEngine discovery platform to tap into novel promising tumor targets found in the dark genome – named camyotopes™ – which have the potential to unlock immunotherapy for large patient populations who currently do not respond. In parallel, the service angle of myNEO Therapeutics, myNEO Intelligence, assists biopharma companies in transforming their decision-making process from trial & error to data-driven decisions using an AI-powered platform. Deriving insights from its expansive library of clinical and molecular data, myNEO Intelligence maps the molecular profiling of cancer patients at an individual level and then correlates the different data points to make data-driven decisions across the drug development life cycle. myNEO Intelligence can identify novel targets and biomarkers, prioritize drug candidates and indications, stratify patient populations and predict treatment response.

Ncardia's hiPSC products portfolio encompasses a broad panel of cardiovascular and neural cells. In addition, the company delivers the Cardioplate™ product line of quality-controlled ready-to-use assay plates.

Novadip Biosciences is a clinical-stage biopharmaceutical company founded to design, develop, and bring to the market a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment. Novadip’s lead allogeneic product, NVD-X3, employs a matrix containing multiple bioactive factors that induce accelerated tissue healing. Designed as an “off-the-shelf” product, NVD-X3 can be shipped and stored at room temperature and offers superior intraoperative handling characteristics. Novadip is also developing NVD-003, an autologous therapy derived from ASCs as a potential single treatment to save limbs and restore mobility in patients with congenital pseudarthrosis of the tibia (CPT). CPT is a rare pediatric bone condition.

Ovizio Imaging Systems, founded in 2009, is a Belgian company that provides the bioprocessing industry with a unique PAT for gathering insight into their cell culture process. The Ovizio platform utilizes label-free, non-destructive, holographic microscopy to detect changes in cell morphology, which is recorded by the microscope and interpreted by AI into meaningful data. The bio-connect, a single-use disposable, allows for closed-loop travel of the cells between the bioreactor and the instrument for analysis. Some applications of interest include cell density and viability metrics, cell counting of cells on microcarriers, transduction or transfection efficiency, cell subtype differentiation, cell activation, and early stage bacterial or fungi contamination. Ovizio’s flagship instrument, the iLineF Pro, is GMP qualified and is commonly used in the cell & gene therapy industry where it is deployed in manufacturing, as well as process development.

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a French-Belgian biotech company that develops an innovative class of active immunotherapies to treat cancers. This cancer vaccine contains proprietary, potent, and scalable plasmacytoid dendritic cell line (PDC*line), whose remarkable characteristics make them excellently suited for immunotherapy. PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors. PDC*line offers unique advantages: - PDC*line is a professional and universal antigen-presenting cell much more potent than conventional (myeloid) Dendritic cells; - unlike conventional autologous Dendritic Cells, PDC*line is very easy to expand in large quantities in bioreactors (no need of maturation factors) and having been exposed in vitro to targeted tumor antigens and irradiated, it can be stored for years. - The off-the-shelf product is thawed and injected to treat any patients with a cancer type expressing the selected antigens and expressing HLA-A2. Of note, different HLA may be used or added to extend the target population. - The approach is very versatile and applicable to any cancer type. Based on a first-in-human phase Ib study in melanoma, PDC*line Pharma focuses on the development of a clinical candidate for lung cancer (PDC*lung) and neoantigens (PDC*Neo). The company regroups a team of 42 persons led by Eric Halioua (CEO) and raised close to 61M€ in equity and loans since its foundation. March 2019, PDC*line Pharma granted exclusive license in South Korea and exclusive option in other Asian countries to LG Chem Life Sciences Company, for the development and commercialization of PDC*lung cancer vaccine for lung cancer. The total deal value is 108M€ (123M$) plus significant tiered royalties on net sales in Asia.

PRECIRIX® is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments. The company is advancing its lead product CAM-H2 through a Phase I/II clinical trial targeting HER2-positive tumors, while further progressing and broadening its oncology pipeline. PRECIRIX' technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy.

RevaTis and University of Liège have developed and patented a specific procedure for the collection, production and storage of autologous muscle-derived mesenchymal stem cells (MdMSC) for immediate therapeutic use or storage for further processing. RevaTis technology is minimally invasive and offers benefits for generating a large number of autologous stem cells. Our sustainable avantages: - patents granted for obtaining pluripotent stem cells by a minimally invasive method for human and veterinary medicine - GMP production in aseptic isolator - Authorization for the production of batches in veterinary and human medicine for clinical studies or research - Accredited stem cell tissue-banks Our Market: The global market for stem cell treatments in animals has a growing rate annual average of 37.27% between 2017 and 2025 and will reach more than 200.000.000 €. In 2017, the global market for equine-level cell therapy was estimated at one third of the global market, In Human Medicine, RevaTis will focuse on the segment "Stem Cell Research and Services. This segment was $ 1,300 million in 2017 to arrive at a size estimate of market of $ 2,400 million in 2022. Our customers: In Vet Medicine, after the approval by agencies, our potential customer are the veterinarians. For Human Application, our markets include partners involved in - R&D Programs on Regenerative Medicine and Cell Therapy - Tissu engineering and 3D-Bio-Printing - Organ on a chip technology. In other words, all companies or Resarch Centers looking for a sourcing of large quantities of MSCs easily to transer in clinic.

UCB – Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients. Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives. UCB – The Facts With approximately 9000 employees in around 40 countries, we are a global biopharmaceutical company headquartered in Brussels, Belgium which invests more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs. A few other reasons that make UCB an amazing place to work: - Promising pipeline that includes several novel molecules; - 2023 Key Financials: € 5.3 billion global revenue Specialties: Neurology, Immunology

For humanity to thrive, we need transformative thinking in how vaccines and therapeutics are designed and produced. At Univercells, we believe in the power of small adaptations to drive big change. We embrace the spirit of evolution in everything we do. We are biotech innovators. We are scientists and entrepreneurs creating transformative platforms for the pharmaceutical and biotech industry, through technology, bioprocess know-how and entrepreneurial spirit.

Univercells Technologies is a global provider of innovative biomanufacturing technologies to achieve cost-effective viral production from R&D to commercial scales. The company offers a comprehensive technology portfolio leveraging the strengths of process intensification and chaining as a direct answer to the growing demand of viral vectors and viral vaccines. Univercells Technologies is committed to helping customers increase performance with minimized footprint and costs today, while anticipating the needs of tomorrow. Building upon years of expertise and capitalizing on technology vetted by world leaders, Univercells Technologies was incorporated in Belgium in 2020 with the support of the Univercells group.

Stem from our advanced R&D on bacteriophages, our Mission is to develop robust modern solutions to fight drug-resistant infections. Antimicrobial resistance (AMR) is a substantial public health issue. From 700 000/y deaths today, the AMR burden is expected to reach ten million/y deaths by 2050, more than cancer. Our approach is to work on personalized, selective, and specific phage therapies against those multi-resistant bacterial infections.

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With 10,000 team members across 50 sites worldwide, West helps support our customers by delivering billions of components and devices each year. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index.